Overview Until about 2016, the majority of vectors used in gene therapy were Adenovirus and Retrovirus vectors. In recent years, a change toward Lentivirus and Adeno-associated virus (AAV) vectors has occurred. This is reflected when looking at the numbers in current clinical trials underway in the gene therapy field.
“The ultimate goal of providing a robust, safe method to transfer solutions in the Manufacturing Facility was achieved and CAI played a major role with this safety initiative.”
INDUSTRY RESOURCES
Download articles and resources from industry events and publications.